- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
Archive - 03 - 2007
March 30, 2007 (Newswise) New research indicates that a significant number of Jamaican adolescents and young adults are being diagnosed with type 2 diabetes, a disease once seen almost exclusively in middle aged and elderly adults. These findings will be presented at the American Association of Clinical Endocrinologists (AACE) Sixteenth Annual Meeting and Clinical Congress which will be held April 11-15 at the Washington State Convention & Trade Center in Seattle.Type 2 diabetes at this age can be considered an indicator of obesity in a society. This research helps confirm that the obesity epidemic is not just an American problem, Marshall Tulloch-Reid, MBBS, DSc, FACE, the studys author said. It is becoming a significant public health challenge in the developing world. In America, adolescents diagnosed with type 2 diabetes are generally between ten and 19 years old, obese, have a family history of type 2 diabetes, and are insulin resistant. Because there is no golden rule to differentiate the types of childhood diabetes, Dr. Tulloch-Reids research is significant as he presents criteria that can be used to identify patients who may have type 2 diabetes. It is the first profile of youth onset type 2 diabetes from the English Speaking Caribbean.As more adolescents become obese at an earlier age, they are at an increased risk of developing type 2 diabetes. According to Tulloch-Reid, Surveys in Jamaica show that nearly 19 percent of adolescents are considered obese. One in five diabetic youth in this study was diagnosed with type 2 diabetes.This original research is being presented by Dr. Tulloch-Reid, along with colleagues from The University of the West Indies and the Kingston Public Hospital. This study will be featured as part of a poster session held during the Sixteenth Annual Meeting and Clinical Congress. Members of the press are invited to attend on Thursday, April 12 and Friday, April 13 from 9:00 a.m. to 9:45 a.m. The preview session will be located at the Convention Center Exhibit Hall 4E in Seattle. Dr. Tulloch-Reid will be available in the media room to discuss his findings on Friday, April 13, from 10:00 a.m. to 11:00 a.m.
March 30, 2007 (Newswise) Aspirin has long been the industry standard for the prevention and treatment of heart attacks. However, for the more than 20 million Americans living with diabetes, the standard dose of aspirin might not provide adequate protection against future heart attacks. Researchers at Sinai Hospital of Baltimore recently demonstrated that aspirin resistance is higher in diabetics with coronary artery disease (CAD) than in non-diabetics at the standard 81mg dose of aspirin. The study (#1019-179) will be presented in its entirety at the 56th Annual Scientific Session of the American College of Cardiology (ACC) in New Orleans on March 26.Most CAD deaths are caused by platelets sticking together and forming blood clots (thrombosis) that block blood flow within arteries, resulting in a heart attack. Aspirin inhibits clotting by specifically blocking an important enzyme, COX-1, which keeps platelets from sticking together. However, some diabetic patients may require a higher aspirin dose to achieve sufficient COX-1 blockade.The occurrence of clotting in patients on aspirin therapy is of major interest within the cardiovascular community. The effect of aspirin dosing in diabetic patients on the prevalence of aspirin resistance remains unclear, said Paul A. Gurbel, M.D., director of the Center for Thrombosis Research at Sinai Hospital of Baltimore and lead author on this study. Our data suggest that there may be a higher risk of thrombosis in diabetic patients during low dose aspirin therapy.The team at the Sinai Center for Thrombosis Research studied 120 aspirin treated patients (30 patients with diabetes) with stable coronary artery disease. Participants were randomly assigned to receive 81mg, 162mg, or 325mg of aspirin daily for four weeks each, for a total of 12 weeks. The response to aspirin was then tested by multiple laboratory methods. It was found that diabetic patients exhibited a higher prevalence of aspirin resistance than non-diabetic patients with 81mg of aspirin.The results of our findings may help to determine the best aspirin dose for diabetic patients, moving physicians away from the one-size-fits-all approach to aspirin therapy, said Gurbel.Sinai Hospital of Baltimore is a member of LifeBridge Health, a regional health organization, which also includes Northwest Hospital Center, Levindale Hebrew Geriatric Center and Hospital, Jewish Convalescent & Nursing Home, and related subsidiaries and affiliates.
One in Ten AMI Patients Have Unrecognized Incident Diabetes
Two New LDL Cholesterol Drugs May Have Big Impact on Heart Disease
COBA Conference Steers Forward in the Fight Against Childhood Obesity
Google Secures Patent for Glucose-Sensing Contact Lens
Medtronic to Use GlucoSitter Artificial Pancreas Software in Future Insulin Pumps - A Big Deal!